



Biotech Daily

Tuesday November 6, 2018

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: REVA UP 9%; AIRXPANDERS DOWN 23%**
- * **QBIOTICS \$26m IPO FOR RAINFOREST CANCER, WOUND DRUGS**
- * **GLOBAL KINETICS PKG IMPROVES PARKINSON'S; SAVINGS**
- * **INVESTORS MUTUAL TAKES 7% OF ELLEX**
- * **ELIXINOL TAKES 50.5% OF ELIXINOL JAPAN**
- * **ELIXINOL CEO PAUL BENHAIM, ASSOCIATES DILUTED TO 63%**
- * **DAVID NEWMAN, GABRIEL ETTENSON, D&G DILUTED TO 10% IN ELIXINOL**

MARKET REPORT

The Australian stock market climbed 0.98 percent on Melbourne Cup Day, Tuesday November 6, 2018, with the ASX200 up 57.1 points to 5,875.2 points.

Cup Day is a Melbourne-only public holiday for the three-minute Melbourne Cup horse race over 2.0 miles (3.2km), but most Australians stop to watch or hear the main race.

Sixteen of the Biotech Daily Top 40 stocks were up, 10 fell, 10 traded unchanged and four were untraded. All three Big Caps fell.

Reva was the best, on the US filing of its third quarter results, up two cents or 9.1 percent to 24 cents, with 24,950 shares traded.

Benitec and Paradigm climbed more than six percent; Genetic Signatures improved 5.2 percent; Immutep was up 4.65 percent; Clinuvel, Dimerix, Telix and Volpara were up three percent or more; Actinogen and Orthocell rose more than two percent; Avita, Cynata and Factor were up more than one percent; with Medical Developments and Nanosonics up by less than one percent.

Airxpanders led the falls for the second day in a row, down 1.3 cents or 23.2 percent to 4.3 cents, with 3.9 million shares traded.

Cyclopharm lost 8.1 percent; Uscom fell 6.7 percent; Osprey was down 3.1 percent; Impedimed, LBT, Polynovo and Universal Biosensors shed more than two percent; Starpharma was down 1.3 percent; with Cochlear, CSL, Resmed and Pro Medicus down by less than one percent.

QBIOTICS

Qbiotics hopes to raise up to \$26 million at 60 cents a share for Australian tropical rainforest-derived anti-cancer and wound healing drugs.

Qbiotics chief executive officer Dr Victoria Gordon told Biotech Daily that “an ASX list is still in the future, probably around 2020 or 2021”.

The company said that it ran complementary programs for human and veterinary pharmaceuticals, so that “much of the preclinical and manufacturing research [could] be shared to reduce overall development costs”.

Qbiotics said that the approach had the potential to de-risk and shorten human drug development, as well as to produce early revenue from marketed veterinary products and its discovery of biologically-active chemicals from nature integrated information about the distribution, habitats and ecological interactions of plants, animals and microbes with an understanding of plant defence, signalling and stress response chemistry.

The company said it had 332,148,069 shares on issue and a \$26 million raising would value the company at \$225,288,841.

The company said that the offer opened yesterday, November 5, with minimum investments of \$6,000 and would close on December 10, 2018.

Qbiotics said its board comprised chairman Rick Holliday-Smith, chief executive officer Dr Gordon, chief scientific officer Dr Paul Reddell, Prof Bruce Robinson, Andrew Denver, Graeme Levy, Dr Steve Ogbourne and Neville Mitchell.

The company said the management team included chief commercial officer Simon Pollard, chief financial officer and company secretary Michael Wenzel, chief operating officer Dr Peter Schmidt, chief veterinary officer Dr Stewart Lowden and chief marketing officer Mary Phipps.

Qbiotics is a public unlisted company.

GLOBAL KINETICS

Global Kinetics says its Personal Kinetigraph improves Parkinson’s disease assessment, management and medication, saving up to \$2,385 per patient a year.

Global Kinetics said that a study of 27,834 Personal Kinetigraph (PKG) users found that “a meaningful proportion of patients had suboptimal [Parkinson’s disease] motor symptoms management, with 54 percent having uncontrolled but likely treatable bradykinesia and 10 percent showing uncontrolled, likely treatable dyskinesia”.

The company said that with PKG use there was “a significant improvement in motor symptoms, demonstrating that the objective measurement data provided by the technology can be used to enhance clinical decision making to improve motor symptom management”.

Global Kinetics said the data was presented in posters at the International Congress of Parkinson’s Disease and Movement Disorders in Hong Kong, October 5 to 9, 2018.

The company said the data showed that the Personal Kinetigraph technology “provided clinically meaningful improvements in [Parkinson’s disease] symptom assessment, management and medication optimization, as well as a projected average cost saving range of \$US962 to \$US1,719 (\$A1,334 to \$A2,385) per patient.

Global Kinetics said the PKG had US Food and Drug Administration-clearance and Conformité Européenne (CE) mark approval and was “a first-of-its-kind wearable technology that provides clinicians with a passive, continuous, objective, ambulatory assessment of the treatable and disabling symptoms of [Parkinson’s disease], including bradykinesia, dyskinesia, and tremor”.

Global Kinetics is a public unlisted company.

[ELLEX MEDICAL LASERS](#)

Investors Mutual says it has increased its substantial shareholding in Ellex from 8,947,315 shares (6.23%) to 10,397,315 shares (7.24%).

The Sydney-based Investors Mutual said that between May 25 and November 1, 2018 it acquired 1,450,000 shares for \$996,659 or 68.7 cents a share.

Ellex was unchanged at 66.5 cents.

[ELIXINOL GLOBAL](#)

Elixinol says it has completed the increase of its ownership of its Japan cannabidiol and hemp food subsidiary to 50.5 percent with an investment of \$2.2 million.

In September, Elixinol said it would acquire 50.5 percent of a restructured but unnamed Japanese business to be named Elixinol Japan (BD: Sep 24, 2018).

The company said the acquisition was through its wholly-owned subsidiary, EXL International Holdings.

Elixinol said its investment of \$2.2 million was “funded by the group’s existing cash reserves and will provide working capital to scale the Japanese business for anticipated growth in hemp-derived cannabidiol, hemp foods and skincare markets.”

Elixinol said that at September 30, 2018, it had \$48.6 million in cash, comprising \$10.7 million in the bank and \$37.9 million from a capital raising (BD: Sep 28, 2018).

Elixinol was up eight cents or 4.2 percent to \$2.00 with 557,548 shares traded.

[ELIXINOL GLOBAL](#)

Paul Benhaim and associates 77,923,131 shareholding has been diluted in a placement from 75.71 percent to 62.56 percent.

In September, Elixinol said it raised \$40 million in a placement (BD: Sep 28, 2018).

Elixinol chief executive officer Paul Benhaim previously told Biotech Daily that the then 75.71 percent holding included escrow staff and investor holdings and that he personally held 53 percent of the company at that time.

Mr Benhaim’s holding includes Raw With Life as trustee for the Benhaim Trading Trust.

[ELIXINOL GLOBAL](#)

David Newman, Gabriel Ettenson and D&G Health says their 12,791,977 shareholding has been diluted in a placement from 12.43 percent to 10.27 percent (BD: Sep 28, 2018).